^
    21h
    KEYNOTE145: ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=161, Completed, Acerta Pharma BV | Active, not recruiting --> Completed | Trial completion date: Apr 2026 --> Oct 2025
    Trial completion • Trial completion date
    |
    Keytruda (pembrolizumab) • Calquence (acalabrutinib)
    1d
    Reduced-Dose Hypofractionated Radiation Therapy (3 Gy × 3 Fractions) for Indolent Non-Hodgkin's lymphoma (POSEIDON): A Multisite Phase 2 Randomized Trial Protocol. (PubMed, Adv Radiat Oncol)
    Secondary endpoints include patient-reported quality of life (FACIT-Fatigue scale), response rate at 3 months posttreatment (Lugano criteria), local control, relapse-free survival, and overall survival. Exploratory analyses will evaluate financial toxicity (COST-FACIT questionnaire), health care expenditure, late toxicity, and the prognostic value of preradiation metabolic imaging parameters, including metabolic tumor volume, total lesion glycolysis, and maximum standardized uptake value, as well as molecular biomarkers such as TP53, MYC, and Ki-67.
    Clinical • P2 data • Journal
    |
    TP53 (Tumor protein P53)
    4d
    Associations between gut microbiota and immune status in untreated B-cell lymphoma patients. (PubMed, Front Immunol)
    Correlations showed Enterobacteriaceae positively linked to Th cells/PCT/TNF and negatively to IL-10 in small B-cell lymphoma; Actinobacteriota correlated with B/T cells/Treg/IFN-β and inversely with IL-2/IL-4/CD8+T cells. This study identifies distinct patterns of gut microbiota dysbiosis across B-cell lymphoma subtypes and explores their correlations with host immune parameters.
    Journal
    |
    CD8 (cluster of differentiation 8) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • IL4 (Interleukin 4) • IFNB1 (Interferon Beta 1)
    10d
    Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=20, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P1/2 trial
    |
    cyclophosphamide • fludarabine IV
    11d
    Computational optimization of MALT1 inhibitors against DLBCL: a QSAR-guided molecular docking and dynamics study. (PubMed, In Silico Pharmacol)
    As this study is purely computational, experimental validation is required to confirm these findings. The online version contains supplementary material available at 10.1007/s40203-025-00466-7.
    Journal
    |
    MALT1 (MALT1 Paracaspase)
    16d
    NCI-2018-00315: Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, City of Hope Medical Center | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    CCND1 (Cyclin D1) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14)
    |
    Imbruvica (ibrutinib) • pevonedistat (MLN4924)
    16d
    Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=35, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Nov 2025 | Trial primary completion date: Jun 2026 --> Nov 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    lenalidomide • Blincyto (blinatumomab)
    16d
    BGB-21447-101: A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies (clinicaltrials.gov)
    P1, N=112, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    BGB-21447
    17d
    Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma (clinicaltrials.gov)
    P2, N=39, Active, not recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial
    |
    Rituxan (rituximab) • Inokai (orelabrutinib)
    17d
    This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=42, Recruiting, LTZ Therapeutics, Inc. | Initiation date: Sep 2025 --> Dec 2025
    Trial initiation date
    21d
    Watch and Wait or Worry and Wait in Indolent Lymphoma (clinicaltrials.gov)
    P=N/A, N=250, Enrolling by invitation, Seoul National University Hospital | Not yet recruiting --> Enrolling by invitation | N=150 --> 250
    Enrollment open • Enrollment change
    21d
    Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=37, Recruiting, David Bond, MD | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    carboplatin • lenalidomide • cyclophosphamide • ifosfamide • etoposide IV • Monjuvi (tafasitamab-cxix)